OverviewSuggest Edit

GeoVax is a biotechnology company specializing in the creation, development, and commercialization of human vaccines to combat HIV/AIDS. Designed for predominant HIV virus subtypes in the developed world, our most advanced vaccine candidate is designed for use in uninfected people to protect them from AIDS should they be exposed to the HIV-1 virus.
TypePublic
Founded2001
HQSmyrna, US
Websitegeovax.com

Latest Updates

Employees (est.) (Jul 2020)6
Revenue (FY, 2019)$1.2 M(+23%)
Share Price (Sept 2020)$0.3 (-9%)
Cybersecurity ratingAMore

Key People/Management at GeoVax

Robert T. McNally

Robert T. McNally

Director
David A. Dodd

David A. Dodd

Chairman, President & CEO
Mark W. Reynolds

Mark W. Reynolds

Chief Financial Officer
Show more

GeoVax Office Locations

GeoVax has an office in Smyrna
Smyrna, US (HQ)
1900 Lake Park Dr SE
Show all (1)

GeoVax Financials and Metrics

GeoVax Revenue

GeoVax's revenue was reported to be $1.18 m in FY, 2019
USD

Revenue (Q2, 2020)

440.6k

Net income (Q2, 2020)

(455.2k)

EBIT (Q2, 2020)

(448.1k)

Market capitalization (22-Sept-2020)

4.6m

Closing stock price (22-Sept-2020)

0.3

Cash (30-Jun-2020)

710.7k

EV

4.6m
GeoVax's current market capitalization is $4.6 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

963.2k1.2m

General and administrative expense

3.0m1.8m1.8m1.8m1.4m2.1m1.2m1.6m1.6m

R&D expense

4.3m3.0m2.9m1.8m1.7m2.0m2.0m1.9m1.9m

Operating expense total

7.2m4.8m4.7m3.6m3.1m4.1m3.2m3.5m3.5m
USDQ2, 2011

Financial Leverage

1.5 x
Show all financial metrics

GeoVax Cybersecurity Score

Cybersecurity ratingPremium dataset

A

98/100

SecurityScorecard logo

GeoVax Online and Social Media Presence

Embed Graph

GeoVax News and Updates

GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine

Atlanta, GA, Sept. 15, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, announced today that its Chief Scientific Officer Emeritus, Harriet L. Robinson, PhD, i…

GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate Against Marburg Virus Showing 100% Protection

Atlanta, GA, Sept. 03, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today the publication of peer-reviewed data of a new vaccine candidate utiliz…

GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer

Atlanta, GA - (NewMediaWire) - August 26, 2020 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, announces today the appointment of Mark J. Newman, Ph.D. as Chief Scientific Officer.Dr. Newman, who pr…

GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients

Atlanta, GA - (NewMediaWire) - August 24, 2020 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, announced today initiation of a Phase 1 clinical study of a combination therapy in HIV-positive patient…

GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines

Atlanta, GA - (NewMediaWire) - August 13, 2020 - GeoVax Labs, Inc., a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today a multi-party collaboration for the development of Sudan ebolavirus (SUDV) and Marburg virus (MARV) v…

GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update

Company Demonstrated Progress on COVID-19 Vaccine Development;Continued Progress in Other Infectious Disease and Immuno-Oncology Programs
Show more

GeoVax Frequently Asked Questions

  • When was GeoVax founded?

    GeoVax was founded in 2001.

  • Who are GeoVax key executives?

    GeoVax's key executives are Robert T. McNally, David A. Dodd and Mark W. Reynolds.

  • How many employees does GeoVax have?

    GeoVax has 6 employees.

  • What is GeoVax revenue?

    Latest GeoVax annual revenue is $1.2 m.

  • What is GeoVax revenue per employee?

    Latest GeoVax revenue per employee is $196 k.

  • Who are GeoVax competitors?

    Competitors of GeoVax include Biogen, Otonomy and MyoKardia.

  • Where is GeoVax headquarters?

    GeoVax headquarters is located at 1900 Lake Park Dr SE, Smyrna.

  • Where are GeoVax offices?

    GeoVax has an office in Smyrna.

  • How many offices does GeoVax have?

    GeoVax has 1 office.